Novel FKS mutations associated with echinocandin resistance in Candida species

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2225-2227

  Garcia Effron, Guillermo ^a   Chua, Daniel Joseph ^b   Tomada, Jon Rupert ^b   DiPersio, Joseph ^b   Perlin, David S ^a   Ghannoum, Mahmoud ^c   Bonilla, Hector ^b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMINO ACID; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANDIDA GLABRATA; CANDIDA TROPICALIS; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS BIOPSY; FEMALE; FKS1 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGEMIA; FUNGUS ISOLATION; FUNGUS MUTANT; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INVASIVE CANDIDIASIS; KIDNEY GRAFT; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SPECIES; TREATMENT DURATION;

ADULT; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 77951243444     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00998-09     Document Type: Article

References (25)

1. Chamilos, G., R. E. Lewis, and D. P. Kontoyiannis. 2006. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrob. Agents Chemother. 50:744-747.
2. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
3. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, and M. el Sherbeini. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl. Acad. Sci. U. S. A. 91:12907-12911.
5. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
6. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
7. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
8. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of Candida krusei isolated with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
9. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
10. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
11. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
12. Kontoyiannis, D. P., I. Vaziri, H. A. Hanna, M. Boktour, J. Thornby, R. Hachem, G. P. Bodey, and I. I. Raad. 2001. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin. Infect. Dis. 33:1676-1681.
13. Krause, D. S., A. E. Simjee, C. van Rensburg, J. Viljoen, T. J. Walsh, B. P. Goldstein, M. Wible, and T. Henkel. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39:770-775.
14. Kuse, E. R., P. Chetchotisakd, C. A. Cunha, C. Barrios, D. Raghunadharao, J. S. Sekhon, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeicher, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely for the Micafungin Invasive Candidiasis Working Group. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 369:519-1526.
15. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans esophagitis. J. Antimicrob. Chemother. 57:705-708.
16. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
17. Osherov, N., G. S. May, N. D. Albert, and D. P. Kontoyiannis. 2002. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 46:2462-2469.
18. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
19. Pasquale, T., J. R. Tomada, M. Ghannoun, J. Dipersio, and H. Bonilla. 2008. Emergence of Candida tropicalis resistant to caspofungin. J. Antimicrob. Chemother. 61:219.
20. Pelletier, R., I. Alarie, R. Lagace, and T. Walsh. 2005. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43:559-564.
21. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
22. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
23. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
24. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh for the Anidulafungin Study Group. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
25. Thompson, G. R., III, N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis II, and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.